Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Dr Reddy’s Laboratories ( (RDY) ).
Dr. Reddy’s Laboratories reported a strong financial performance for the fiscal year 2025, achieving record revenues of over $3.8 billion and surpassing $1 billion in EBITDA for the first time. The company’s revenue growth was driven by the strategic acquisition of a consumer healthcare business in Nicotine Replacement Therapy (NRT) and contributions from its generics portfolio. Despite a decline in gross profit margins due to reduced manufacturing overhead leverage, the company maintained stable margins for the year. The company also increased its R&D investments to enhance its pipeline, focusing on small molecules, biosimilars, and novel oncology assets, indicating a commitment to long-term growth.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. The company is known for its diverse range of pharmaceutical products, including generics, biosimilars, and active pharmaceutical ingredients (APIs), with a market focus that spans across geographies.
Average Trading Volume: 2,162,754
Technical Sentiment Signal: Buy
Current Market Cap: $11.91B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.